Dinesh Khanna, MD, MSc, is Professor of Medicine and Director, University of Michigan Scleroderma Program. He holds the Frederick G.L. Huetwell Professorship in Rheumatology. Dr. Khanna has published over 250 peer-reviewed articles and book chapters. He is the Principal Investigator on National Institutes of Health and industry-sponsored clinical studies. He is currently leading trials of abatacept (http://umich.edu/~asststdy/), riociguat, pirfenidone, and tociluzimab in scleroderma.
Dr. Khanna also serves as a reviewer for several professional journals, society committees and training programs, and grant applications and has published in Lancet and JAMA. His current research focus is on developing, validating, and refining outcome measures in rheumatic diseases and designing controlled trials. He received the 2011 Doctor of the Year award from the Scleroderma Foundation and the prestigious 2015 Henry Kunkel Young Investigator Award from the American College of Rheumatology.
More information is available at www.med.umich.edu/scleroderma.